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Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is an autosomal dominant dementia that
is characterized by the retention of polymers of neuroserpin as inclusions within the endoplasmic reticulum
(ER) of neurons. We have developed monoclonal antibodies that detect polymerized neuroserpin and have
used COS-7 cells, stably transfected PC12 cell lines and transgenic Drosophila melanogaster to characterize
the cellular handling of all four mutant forms of neuroserpin that cause FENIB. We show a direct correlation
between the severity of the disease-causing mutation and the accumulation of neuroserpin polymers in cell
and ﬂy models of the disease. Moreover, mutant neuroserpin causes locomotor deﬁcits in the ﬂy allowing us
to demonstrate a direct link between polymer accumulation and neuronal toxicity.
INTRODUCTION
Conformational diseases are a group of disorders caused by
aberrant intermolecular interactions, aggregation and depo-
sition of proteins (1). These diseases are typiﬁed by
members of the serine proteinase inhibitor (serpin) superfam-
ily in which point mutations result in the accumulation of
polymerized proteins during their biosynthesis within the
cell (2,3). The structural basis for serpin polymerization has
been elucidated and shown to result from the sequential
linkage between the reactive centre loop of one molecule
and b-sheet A of another (4–9). The retention of polymerized
serpins within a cell can cause disease through a ‘toxic gain of
function’ while the lack of secretion of these important pro-
teinase inhibitors causes the uncontrolled activation of proteo-
lytic cascades and hence disease through a ‘loss of function’.
Mutations in the serpins have been implicated in diseases as
diverse as liver cirrhosis, emphysema, thrombosis,
angio-oedema and dementia (10,11). In view of the common
mechanism, we have grouped the conditions that result from
serpin polymerization as a new class of disease that we have
termed as serpinopathies (2,10).
FENIB is a serpinopathy that presents as an autosomal
dominant dementia (12–14). This disease is characterized his-
tologically by inclusions of mutant neuroserpin within the
endoplasmic reticulum (ER) of cortical and subcortical
neurons. Wild-type neuroserpin is secreted from the axonal
growth cones of the central and peripheral nervous system
and inhibits tissue plasminogen activator (15–19). It has
been implicated in regulation of axonal growth, reduction of
seizure activity, limitation of damage during cerebral infarc-
tion and control of emotional behaviour and memory
(20,21). Neuroserpin is found in dense-core secretory vesicles
typical of the regulated secretory pathway in cells of the pitu-
itary and adrenal glands (22), in a pheochromocytoma (PC12)
cell line that over-expresses neuroserpin (23) and in primary
neuronal cultures (24). Recently, a signal peptide for regulated
secretion has been identiﬁed in the C-terminus of the protein
and shown to be functional in anterior pituitary cells
(AtT-20 cells) (24).
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that cause the dementia FENIB. All four mutations affect
the stability of the shutter region of neuroserpin and show a
striking correlation between the predicted molecular instability
and the number of neuroserpin inclusions and an inverse cor-
relation with the age of onset of dementia (14). Two of these
mutants, S49P and S52R neuroserpin, have been characterized
in detail (18,25,26). We have shown that recombinant puriﬁed
S49P and S52R neuroserpin form polymers at 378C, and that
S52R polymerizes 15 times faster than S49P neuroserpin.
Moreover, both mutations cause the retention of neuroserpin
as ordered polymers within the ER of COS-7 cells (27) and
give rise to intracellular inclusion bodies in the brains of trans-
genic mice (28). The S52R neuroserpin mutation causes more
accumulation in both models in keeping with the more severe
clinical phenotype. There is no data on the cellular handling of
H338R and G392E neuroserpin which are associated with the
most severe forms of the disease (14).
We report here on the cellular processing of all four mutants
ofneuroserpinthatcausethedementiaFENIB.Wehavecharac-
terized the handling of the mutant proteins in COS-7 cells, in
stably transfected PC12 cell lines and in transgenic Drosophila
melanogaster. We have also developed a conformer-speciﬁc
monoclonal antibody that detects polymerized neuroserpin
and have used it to show that the intracellular accumulation of
neuroserpin polymers, in both tissue culture cells and neurons
of ﬂies, correlates with the degree of instability of the mutant
protein predicted by molecular modelling. Moreover, we
show that mutant neuroserpin causes locomotor deﬁcits in the
ﬂy, allowing us to demonstrate a direct link between polymer
accumulation and neuronal toxicity.
RESULTS
H338R and G392E neuroserpin accumulate as polymers
within the endoplasmic reticulum of COS-7 cells
COS-7 cells were transfected with wild-type, H338R or
G392E neuroserpin and co-stained for neuroserpin and resi-
dent proteins of the secretory pathway (Fig. 1A). Wild-type
neuroserpin was distributed in a reticular pattern that
co-localized with calreticulin within the ER (top left panel)
as reported previously (27) and as expected for a secreted gly-
coprotein. Both H338R and G392E neuroserpin (middle and
right panels) formed the characteristic punctate inclusions
that we have described for other mutants of neuroserpin that
cause FENIB (27). These inclusions co-localized with calreti-
culin (top middle and right panels) indicating that they were
contained within the ER. Co-staining with the GM130 Golgi
marker showed that a fraction of the wild-type protein
(bottom left panel) but none of the mutant protein (bottom
middle and right panels) trafﬁcked through this organelle.
The intracellular localization of wild-type and mutant neu-
roserpin was conﬁrmed by digestion of proteins labelled
with
35S-methionine and -cysteine with endoglycosidase H
(Fig. 1B). There was almost no detectable wild-type neuroser-
pin in the cell lysates after a 6 h chase (Fig. 1B, wild type,
lanes C). However, there was an intracellular band of
50 kDa in cells transfected with both mutants of neuroserpin
Figure 1. Mutant H338R and G392E neuroserpin accumulate as polymers
within the ER. (A) Confocal microscopy analysis of COS-7 cells cultured
for 48 h after transfection with wild-type, H338R or G392E neuroserpin and
stained for neuroserpin (red) and the ER-resident protein calreticulin or the
Golgi-resident protein GM130 (green). Only the merged images are shown
in which yellow colour corresponds to areas with overlapping red and green
staining. The nucleus appears blue due to DNA staining with DAPI. Scale
bar: 10 mm. (B) Endoglycosidase-H (eH) digestion of samples from cells
transfected with wild-type or each mutant neuroserpin that were
pulsed-labelled and chased for 6 h. Cells lysates (C) and culture media (M)
were analysed by immunoprecipitation and 8% w/v SDS–PAGE. Arrow:
fully glycosylated and secreted neuroserpin, 55 kDa; arrowhead: intracellular
neuroserpin intermediate, 50 kDa; black and white arrow: deglycosylated
intracellular neuroserpin, 45 kDa; the asterisk indicates a second band of
extracellular wild-type neuroserpin due to extracellular proteolysis; the dash
indicates a slower migrating band of extracellular G392E neuroserpin. (C)
7.5% w/v acrylamide non-denaturing PAGE and western-blot analysis for neu-
roserpin in cell lysates (C) and culture media (M) from COS-7 cells trans-
fected with wild-type or mutant neuroserpin or with a control plasmid
expressing luciferase (Lucif.). Cells were cultured for 72 h after transfection.
Arrow: wild-type and S52R neuroserpin monomers; arrowhead: S49P neuro-
serpin monomer; curly bracket: neuroserpin polymers.
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shifted to 45 kDa after digestion with endoglycosidase H
(Fig. 1B, H338R and G392E, lanes þ/C, black and white
arrow), showing that it still contained unmodiﬁed poly-
mannose N-glycans typical of ER proteins. None of the neuro-
serpin proteins in the culture media (Fig. 1B, lanes M, black
arrow, 55 kDa) were sensitive to the endoglycosidase H diges-
tion, as expected for proteins that have acquired complex
oligosaccharide structures in the Golgi complex. Wild-type
neuroserpin in the culture media contained an additional
lower band (Fig. 1B, wild type, lanes M, asterisk) due to pro-
teolysis over the 6 h chase period, while both mutant forms of
neuroserpin were resistant to proteolysis due to their poly-
meric conformation (Fig. 1C). An additional band of higher
molecular mass was seen for G392E neuroserpin, both
within the cells (Fig. 1B, G392E, lane 2/C) and in the
culture media (Fig. 1B, G392E, lanes þ/M and 2/M, dash).
Both intracellular species reduced to 45 kDa after the treat-
ment with endoglycosidase H, suggesting that they correspond
to proteins contained within the ER and that the difference
between them is due to N-glycan modiﬁcation.
It has been predicted that the H338R and G392E mutations
cause neuroserpin to form polymers (14). This was investi-
gated by transfecting COS-7 cells with wild-type or mutant
neuroserpin and assessing the cell lysates and culture media
by non-denaturing PAGE and western-blot analysis
(Fig. 1C). The previously characterized S49P and S52R
mutants of neuroserpin (27) were included for comparison.
Wild-type neuroserpin was present solely as a monomer in
the culture medium (arrow), whereas all the neuroserpin
mutants formed polymers that were found in both the cell
lysates and the culture media (curly bracket). In contrast to
S49P and S52R neuroserpin (arrow and arrowhead in
Fig. 1B), no monomeric H338R or G392E neuroserpin was
detectable in the media. Moreover, G392E neuroserpin
formed the highest molecular mass polymers in keeping with
the prediction that it has the greatest propensity to polymerize.
Taken together, these results show that both H338R and
G392E neuroserpin form polymers that accumulate within
the ER.
Detection of polymers of mutant neuroserpin with an
anti-polymer monoclonal antibody
We developed four conformation speciﬁc anti-neuroserpin
monoclonal antibodies in order to characterize neuroserpin
in our model systems of disease. We used a sandwich
ELISA to determine the afﬁnities of the monoclonal antibodies
for recombinant monomeric wild-type neuroserpin and mono-
meric and polymeric S49P neuroserpin. The monoclonal anti-
bodies 1A10, 10B8 and 10G12 showed similar characteristics,
so we present the results for 1A10 only. This monoclonal anti-
body detected all three antigens with similar high afﬁnities
(Fig. 2A, top), whereas the 7C6 monoclonal antibody
showed higher afﬁnity for polymerized S49P neuroserpin
(Fig. 2A, bottom). Similar results were obtained using recom-
binant monomeric and polymeric S52R neuroserpin as the
antigen (data not shown). The monoclonal antibodies were
then assessed for their ability to detect total or polymerized
neuroserpin in a sandwich ELISA with different ratios of
recombinant wild-type neuroserpin monomer and S52R
neuroserpin polymers as antigens. 1A10 showed a similar afﬁ-
nity for all antigen mixtures (Fig. 2B, top), while 7C6 showed
comparatively low afﬁnity for the wild-type monomer but
increasing afﬁnity with increasing proportion of S52R poly-
mers (Fig. 2B, bottom). We then used these monoclonal anti-
bodies in a sandwich ELISA assay to assess the presence of
neuroserpin monomers and polymers in COS-7 cells trans-
fected with wild-type or mutant neuroserpin. The monoclonal
antibody 1A10 detected neuroserpin in all the cell lysates
(Fig. 2C, top) with higher signals in the lysates from cells
expressing mutant neuroserpin. In contrast, 7C6 gave a clear
signal in the lysates from cells expressing mutant neuroserpin
but failed to detect neuroserpin in cells expressing wild-type
monomeric protein (Fig. 2C, bottom). Similar results were
obtained when the culture media was analysed with the
same technique (results not shown). These results demonstrate
the ability of 7C6 to speciﬁcally detect polymerized neuroser-
pin and conﬁrm its presence in lysates and culture media of
cells expressing the mutant proteins.
We then used the 7C6 monoclonal antibody to localize neu-
roserpin polymers in cell models of disease. Total neuroserpin
was detected with a polyclonal antibody in COS-7 cells trans-
fected with wild-type neuroserpin or one of each of the four
mutants of neuroserpin that cause FENIB (Fig. 2D, red stain-
ing). In contrast, only cells expressing mutant neuroserpin
showed staining with the 7C6 antibody (Fig. 2D, green stain-
ing). Cells stained in the same way with the anti-neuroserpin
polyclonal antibody and the monoclonal antibody 1A10
showed overlapping red and green staining for all neuroserpin
variants (data not shown). These data show that intracellular
polymers contribute to the punctate accumulations of mutant
neuroserpin in cell models of FENIB [(27) and the present
work], and together with our ELISA results shown above
demonstrate that our monoclonal antibodies are a valuable
tool for the detection and quantitation of total and polymerized
neuroserpin.
Accumulation of neuroserpin polymers correlates with
increasing severity of dementia in patients with FENIB
The generation of the H338R and G392E mutants of neuroser-
pin allowed us to assess the relationship between genotype and
phenotype for all four known mutations that cause FENIB. We
found a striking correlation between the number of COS-7
cells that contained neuroserpin inclusions and the severity
of FENIB caused by each mutation (Fig. 3A, correlation coef-
ﬁcient R
2 ¼ 0.93). Next, we assessed the secretion of each
neuroserpin variant (Fig. 3B). Neuroserpin was detected as a
50 kDa band in the cell lysates and as a 55 kDa band in the
culture media, corresponding to partial and full processing
of the glycan chains, respectively (Fig. 3B). After 72 h in
culture, no detectable wild-type neuroserpin remained inside
the cells and a strong 55 kDa band was detected in the
culture medium, together with a faster migrating band due to
proteolysis (Fig. 3B, Wt, lane C versus lane M). In contrast,
at the same time point, we still detected intracellular mutant
neuroserpin (Fig. 3B, S49P, S52R, H338R and G392E, lanes
C), with the amount of neuroserpin in the cell lysates
correlating with the intracellular accumulation observed by
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was found for secretion when assessed by western-blot analy-
sis (Fig. 3B) and quantiﬁed by sandwich ELISA (Fig. 3C, cor-
relation coefﬁcient R
2 ¼ 0.82).
Pulse-chase analysis was used to quantify the differences in
secretion between wild-type and the four mutants of neuroser-
pin. COS-7 cells transfected with each protein variant were
pulse-labelled with
35S-methionine and -cysteine for 15 min
and chased for 6 h. Neuroserpin was detected as a 50 kDa
intracellular band corresponding to the ER form (Fig. 3D,
lanes C, arrowhead) and a 55 kDa band in the culture media
corresponding to mature secreted neuroserpin with fully pro-
cessed glycans (Fig. 3D, lanes M, arrow). The intracellular
fraction of G392E neuroserpin also contained a 55 kDa band
(Fig. 3D, lower panel, G392E, lane C) and a slower migrating
band was detected in the culture medium (Fig. 3D, lower
panel, G392E, lane M, asterisk). The percentage of radio-
labelled neuroserpin in the cell lysates and culture media for
each variant was quantiﬁed by autoradiography (Fig. 3D,
graph). The amount of secreted neuroserpin decreases with
Figure 2. Detection of mutant neuroserpin polymers with an anti-polymer monoclonal antibody. (A) Binding of monoclonal antibodies 1A10 and 7C6 in a sand-
wich ELISA to recombinant monomeric wild-type neuroserpin (Wt) and monomeric (mon) or polymerized (pol) S49P neuroserpin as the antigens. (B) Binding of
monoclonal antibodies 1A10 and 7C6 in a sandwich ELISA using different proportions of recombinant wild-type monomeric neuroserpin (mon) and polymerized
S52R neuroserpin (pol) as the antigens. These are shown as the percentage of each species, for example mon75-pol25 is a mixture that is 75% monomer and 25%
polymer. (C) Cell lysates from COS-7 cells transfected with wild-type neuroserpin or mutants of neuroserpin that cause FENIB (S49P, S52R, H338R, G392E)
were analysed by sandwich ELISA using either 1A10 or 7C6 to detect neuroserpin. (D) Confocal microscopy analysis of COS-7 cells transiently transfected with
each neuroserpin variant were immunostained for total neuroserpin with a rabbit anti-neuroserpin polyclonal antibody (red) and for neuroserpin polymers with
monoclonal antibody 7C6 (green). The nucleus appears blue due to DNA staining with DAPI. Scale bar: 10 mm.
1530 Human Molecular Genetics, 2008, Vol. 17, No. 11increasing propensity to form polymers: 70% of the wild-type
neuroserpin was found in the culture medium and 59, 55, 45
and 38% of S49P, S52R, H338R and G392E neuroserpin,
respectively (correlation coefﬁcient R
2 ¼ 0.59).
These results demonstrate that all known mutations in neu-
roserpin that cause polymerization lead to decreased secretion
of the mutant protein, and that the defect in trafﬁcking
increases with increasing propensity to form polymers.
Polymer accumulation and decreased regulated secretion
of mutant neuroserpin in PC12 cells
Neuroserpin is constitutively secreted in COS-7 cells.
However, in glandular and neural tissues, neuroserpin is traf-
ﬁcked through the regulated secretory pathway, stored in
dense core vesicles and secreted upon stimulation (22–24).
We therefore developed stably transfected PC12 cell lines
Figure 3. Increasing intracellular accumulation of mutant neuroserpin polymers correlates with increasing severity of FENIB. (A) Percentage of transfected
COS-7 cells showing punctate neuroserpin accumulation 24 h after transfection. Neuroserpin accumulation was quantiﬁed by counting more than 100 transfected
cells per experiment in three independent experiments for each neuroserpin variant. Each experiment was counted blind and cells were scored as containing
punctate accumulation if there were at least 10 discrete protein ‘spots’ per cell. Percentages are averages +SEM, and the differences were statistically signiﬁcant
when analysed by one-way ANOVA (P , 0.0001) followed by a post-test for linear trend (R
2 ¼ 0.93, P , 0.0001). (B) Cell lysates (C) and culture media (M)
of COS-7 cells transfected with wild-type or each mutant neuroserpin or with a control plasmid expressing luciferase (Lucif.) were analysed 72 h after transfec-
tion by 8% w/v acrylamide SDS–PAGE and western-blot analysis with an anti-neuroserpin antibody. NS, control lane loaded with 20 ng of puriﬁed recombinant
neuroserpin. Black arrow: fully glycosylated and secreted neuroserpin, 55 kDa; arrowhead: intracellular neuroserpin intermediate, 50 kDa; black and white
arrow: non-glycosylated recombinant neuroserpin used as a control, 45 kDa. (C) The amount of total neuroserpin was determined by sandwich ELISA in
cell lysates and culture media of COS-7 cells 72 h after transfection with wild-type or each mutant neuroserpin. The graph shows the proportion of neuroserpin
that was present in the culture media. Values are averages +SEM from three independent repeats, and the differences were statistically signiﬁcant when ana-
lysed by one-way ANOVA (P , 0.0001) followed by a post-test for linear trend (R
2 ¼ 0.82, P , 0.0001). (D) Cells transfected with wild-type or each mutant
neuroserpin were pulsed-labelled and chased for 6 h. Cells lysates (C) and culture media (M) were analysed by immunoprecipitation and 8% w/v SDS–PAGE.
Arrow: fully glycosylated and secreted neuroserpin, 55 kDa; arrowhead: intracellular neuroserpin intermediate, 50 kDa; asterisk: a slower migrating second band
in the culture medium of cells transfected with G392E neuroserpin. The graph shows the quantitation of the pulse-chase experiment using a phosphorimager. The
amount of radioactivity in each sample is expressed as the percentage of the total radioactivity for each neuroserpin variant. Values are averages +SEM from
ﬁve independent repeats, and the differences were statistically signiﬁcant when analysed by one-way ANOVA (P , 0.0001) followed by a post-test for linear
trend (R
2 ¼ 0.59, P , 0.0001).
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or mutants that cause moderate (S52R; PC12-S52R) and
severe (G392E; PC12-G392E) forms of FENIB (Fig. 4A).
Neuroserpin was detected by SDS–PAGE and western-blot
analysis in lysates of the three cell lines following induction
with doxycycline (Fig. 4A, top panel, lanes On). The
steady-state level of neuroserpin was lower for cells expres-
sing the mutant proteins. This must be due to increased
Figure 4. Trafﬁcking of wild-type and mutant neuroserpin in stably transfected PC12 cell lines. (A) Lysates from PC12-Tet-On, PC12-Wt, PC12-S52R and
PC12-G392E cells cultured with (on) or without (off)1 0mg/ml doxycycline to induce neuroserpin expression were analysed by SDS and non-denaturing
PAGE followed by western-blot analysis with an anti-neuroserpin polyclonal antibody. The membrane from the SDS–PAGE was also analysed with an anti-
GAPDH antibody as a loading control. (B) Neuroserpin from lysed PC12-Tet-On, PC12-Wt, PC12-S52R and PC12-G392E cells induced for 4 days was immu-
noprecipitated with the 1A10 anti-neuroserpin monoclonal antibody and treated (þ) or not (2) with endoglycosidase H (eH) and analysed by SDS–PAGE and
western blot analysis. S52R and G392E neuroserpin were sensitive to endoglycosidase H (arrow) whereas wild-type neuroserpin was resistant (arrowhead). (C)
Immuno-co-localization of wild-type and G392E neuroserpin with resident proteins of the secretory pathway. PC12-wildtype and PC12-G392E cells were differ-
entiated to a neuronal phenotype by plating in collagen and treating with NGF (150 ng/ml) for 7 days, and then induced to express neuroserpin with 10 mg/ml
doxycycline for 3 days. Cells were co-stained with either a polyclonal anti-neuroserpin antibody or one of the anti-neuroserpin monoclonal antibodies (1A10 for
total neuroserpin or 7C6 for neuroserpin polymers) and antibodies against calreticulin (ER), GM130 (Golgi), ERGIC-53/p58 (ERGIC) or chromogranin A (traf-
ﬁcked through the regulated secretory pathway). The colour corresponding to each antibody (red or green) is shown above the ﬁgure and only the merged images
are presented. Yellow represents areas of overlapping red and green. The nucleus appears blue due to DNA staining with DAPI. Scale bar: 10 mm. (D) PC12-Wt,
PC12-S52R and PC12-G392E cells were induced to express neuroserpin for 3 days with 10 mg/ml doxycycline and then incubated for 15 min with control or
release buffer containing 5 or 55 mM KCl, respectively, to assess regulated secretion from dense core secretory granules. Neuroserpin was analysed in cell lysates
and buffer solutions by SDS–PAGE and western blot and quantiﬁed by sandwich ELISA. The graph shows the averages for three independent experiments
analysed by ELISA, expressed as percentages +SEM. The amount of neuroserpin secreted from each cell line when treated with release buffer was statistically
different when analysed by one-way ANOVA (P ¼ 0.0003) followed by a post-test for linear trend (R
2 ¼ 0.93, P ¼ 0.0001).
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as the three cell lines expressed similar levels of protein
when assessed by the pulse-chase analysis (results not
shown) and both mutant proteins accumulated within the
cells upon treatment with the proteasomal inhibitors lactacys-
tin and MG132 (data not shown). Non-denaturing PAGE and
western-blot analysis of cell lysate from PC12-Wt cells
showed a single band characteristic of monomeric wild-type
neuroserpin (Fig. 4A, bottom panel, lane On/Wt, arrow),
while PC12-S52R and PC12-G392E cell lysates showed
high molecular mass ladders typical of polymers (Fig. 4A,
bottom panel, lanes On/S52R and On/G392E, curly bracket).
A weak monomeric band was also apparent in lysates from
the PC12-S52R cells (Fig. 4A, bottom panel, lane On/S52R,
arrow).
Neuroserpin from each of the cell lysates was characterized
by immunoprecipitation with the 1A10 monoclonal antibody
followed by endoglycosidase H digestion (Fig. 4B). The immu-
noprecipitate from PC12-Wt cells contained a single band that
was unchanged following treatment with endoglycosidase H
(Fig. 4B, Wt 2/þ), suggesting that at steady state the bulk of
wild-type neuroserpin is present as mature protein in our PC12
cells. In contrast, neuroserpin immunoprecipitated from
PC12-G392E cells ran as a single band of higher molecular
mass that decreased in size following treatment with endoglyco-
sidase H (Fig. 4B, G392E 2/þ). Thus, this protein had not traf-
ﬁcked to the Golgi apparatus. Lysates from PC12-S52R cells
showed an intermediate situation with two neuroserpin bands
in the immunoprecipitate, one similar in size to wild-type neu-
roserpin and a higher molecular mass band similar to that of
G392E neuroserpin. This band also decreased in size after treat-
ment with endoglycosidase H (Fig. 4B, S52R2/þ).
Taken together, these results suggest that there are two
different species of neuroserpin that can be differentiated
after immunoprecipitation: monomeric wild-type and S52R
neuroserpin, which are insensitive to endoglycosidase H diges-
tion and run as single bands on non-denaturing PAGE, and
polymers of S52R and G392E neuroserpin, which are endogly-
cosidase H sensitive and form high molecular mass ladders on
non-denaturing PAGE.
The trafﬁcking of neuroserpin was then assessed in PC12
cells that were differentiated into neurons by plating on col-
lagen and treatment with nerve growth factor prior to the
expression of neuroserpin. The distribution of total neuroser-
pin was characterized with an anti-neuroserpin polyclonal
antibody while neuroserpin polymers were identiﬁed with
the 7C6 monoclonal antibody. There was strong staining for
wild-type neuroserpin in the periphery of the cells and the
tips of neurites (Fig. 4C, wild type, outlined neurite tips)
where it co-localized with chromogranin A (Fig. 4C, top,
neuroserpin/chromogranin A, outlined neurite tip), a marker
for dense core vesicles. This is in keeping with the storage
of wild-type neuroserpin in dense core vesicles ready for regu-
lated secretion. No polymers were detected with the 7C6 anti-
body in PC12-Wt cells (Fig. 4C, wild-type, NS polymers/ER).
In contrast, G392E neuroserpin was found mainly in the cell
body of PC12 cells where it formed punctate accumulations
typical of mutant neuroserpin (Fig. 4C, G392E). These
inclusions stained positive for both total neuroserpin and neu-
roserpin polymers (Fig. 4C, G392E, NS polymers/ER and
Neuroserpin/ER). The analysis of PC12-S52R cells showed a
mixture of the staining seen for wild-type and G392E neuro-
serpin (data not shown).
We concentrated on the wild-type and G392E neuroserpin
cell lines for further characterization of neuroserpin trafﬁcking
by immunocytochemistry. Wild-type neuroserpin did not
co-localize with calreticulin in the ER or ERGIC-53/p-58 in
the ER Golgi intermediate compartment (ERGIC) and only
some cells showed co-localization with GM130 in the Golgi
compartment (Fig. 4C, wild type, neuroserpin/ER, neuro-
serpin/ERGIC, neuroserpin/Golgi). G392E neuroserpin
co-localized with calreticulin within the ER even when the
punctate inclusions were found within the neurites (Fig. 4C,
G392E, neuroserpin polymers/ER and neuroserpin/ER, out-
lined neurite tip), but there was no co-localization with the
ERGIC (Fig. 4C, G392E, neuroserpin/ERGIC) or Golgi
markers (Fig. 4C, G392E, neuroserpin/Golgi). There was
poor co-localization with chromogranin A and none within
the neurites, indicating the absence of mutant neuroserpin in
dense core secretory vesicles (Fig. 4C, G392E, neuroserpin/
chromogranin A, outlined neurite tip).
In view of the co-localization of wild-type neuroserpin with
chromogranin A, we assessed the regulated secretion of neuro-
serpin from each cell line upon stimulation with 55 mM KCl
for 15 min. Cell lysates and media were analysed by SDS–
PAGE and western-blot analysis and by sandwich ELISA.
Treatment with K
þ resulted in the secretion of 30% of the
wild-type neuroserpin, 20% of S52R neuroserpin (detectable
only by ELISA) and no neuroserpin from cells expressing
G392E neuroserpin (Fig. 4D western blot and graph,
release). The same results were obtained with a second inde-
pendent clone for each cell line (data not shown). The
reduction in regulated secretion was speciﬁc for neuroserpin,
since similar amounts of secreted chromogranin A were
detected by western-blot for all the PC12 cell lines (Fig. 4D,
chromogranin A/release).
Our results demonstrate that the stably transfected PC12 cell
lines reproduce the physiological trafﬁcking of neuroserpin
through the regulated secretory pathway. In this model
system, wild-type neuroserpin was synthesized, normally traf-
ﬁcked and stored as mature endoglycosidase H resistant
protein in dense-core secretory vesicles at the tip of the neur-
ites, from where it was released upon membrane depolariz-
ation. In contrast, mutant G392E neuroserpin was found in a
pre-Golgi compartment and was not secreted upon stimulation.
S52R neuroserpin showed an intermediate phenotype, with a
fraction of the protein being trafﬁcked and secreted and the
remainder being retained in the ER. This demonstrates that
increasing propensity to polymerization underlies increasing
trafﬁcking defects in correlation with human disease in the
context of an expression system that is closer to human
physiology.
The neuronal dysfunction underlying FENIB is caused
by the accumulation of neuroserpin polymers
The expression of S52R and G392E neuroserpin in stably
transfected PC12 cell lines did not result in demonstrable
apoptosis as assessed by staining with antibodies against
annexin V and active caspase-3, up to 12 days after induction
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polymer accumulation was assessed at the organismal level
by generating Drosophila strains that expressed either wild-
type neuroserpin or each of the variants that cause FENIB,
under the control of a neuronal promoter. The expression of
wild-type neuroserpin was toxic to the ﬂies, therefore the
key P1 and P10 amino acids of neuroserpin, which are
located in the reactive centre loop and form the pseudosub-
strate for the target proteinase, were changed from Met-Arg
to Pro–Pro. This mutation rendered recombinant neuroserpin
puriﬁed from E. coli inactive as an inhibitor of tPA (29), but
had no effect on the rate of polymerization (data not
shown). The expression of wild-type neuroserpin with the
P1–P10 Pro–Pro substitution was no longer toxic to the ﬂy
(29). We therefore expressed all neuroserpin variants with
Pro–Pro in the P1–P10 positions in the nervous system of
the ﬂy under the control of the elav
c155 2Gal4 driver. At
least ﬁve independent transgenic lines were generated for
each genotype. Neuroserpin was detectable in ﬂy homogenates
in all lines by sandwich ELISA, although the signal was lower
in ﬂies expressing the wild-type protein probably as a result of
efﬁcient clearance (Fig. 5A). We selected one line for each
genotype that was representative of the level of accumulation
of neuroserpin. These lines were then characterized in more
detail.
The distribution of neuroserpin in ﬂy brain sections was
assessed by immunohistochemistry with the monoclonal anti-
body 1A10. There was intracellular accumulation of each of
the mutant proteins in the cell bodies of heterogeneously dis-
tributed cortical neurons. This was despite elav
c155 2Gal4
driving ubiquitous neuronal expression (Fig. 5B S49P, S52R,
H338R and G392R panels, and enlarged details for S52R
and G392E). Cells containing accumulated neuroserpin were
most abundant in ﬂies expressing the H338R and G392E
mutants of neuroserpin that cause severe FENIB. The low
levels of wild-type neuroserpin already observed by ELISA
precluded its localization by immunohistochemistry
(Fig. 5B, Wt).
The anti-polymer monoclonal antibody 7C6 does not stain
parafﬁn sections; we were therefore unable to correlate the
accumulation of mutant neuroserpin with the presence of poly-
mers by immunohistochemistry. We were, however, able to
detect and quantify polymerized neuroserpin in brain homo-
genates by sandwich ELISA using the 7C6 monoclonal anti-
body (Fig. 5C). There was marked accumulation of
neuroserpin polymers in ﬂies expressing mutant neuroserpin,
particularly the highly polymerogenic H338R and G392E
mutants. This correlated well with the results obtained by
immunohistochemistry and provides evidence that the signal
detected by immunohistochemistry corresponds to the
accumulation of polymers. We were unable to detect polymers
in the brains of ﬂies expressing wild-type protein (Fig. 5C).
Having conﬁrmed that neuroserpin polymer accumulation
only occurs in ﬂies expressing disease-causing variants, we
then examined the effects of mutant neuroserpin expression
on survival of ﬂies and their neurological function. There
was no difference in median survival of ﬂies expressing wild
type (39 days, n ¼ 60), S49P (41 days, n ¼ 60), S52R (39
days, n ¼ 60), H338R (39 days, n ¼ 60) or G392E (45 days,
n ¼ 60) neuroserpin when compared to control ﬂies
(elav
c155   w
1118, 39 days, n ¼ 60) (Fig. 5D). Locomotor
function was normal in ﬂies expressing wild-type and
mutant neuroserpin at eclosion (emergence of the adult from
the pupa) but deteriorated rapidly in ﬂies expressing mutant
neuroserpin. By day 30 after eclosion, there were clear deﬁcits
in climbing that correlated with the level of accumulation of
neuroserpin polymers (correlation coefﬁcient 0.84, P , 0.05;
Fig. 5E). Additionally, the expression of neuroserpin in the
eye with the GMR-Gal4 driver caused a rough eye phenotype
for all the mutants that form polymers but not in ﬂies expres-
sing the wild-type protein (data not shown). These data
provide a direct link between the accumulation of neuroserpin
polymers over time and neurological dysfunction.
DISCUSSION
The neurodegenerative disorder familial encephalopathy with
neuroserpin inclusion bodies (FENIB) results from point
mutations in the neuroserpin gene. We have investigated
how four different mutations in neuroserpin cause dementia
by assessing the mechanism of disease at the cellular and orga-
nismal level. We show that all four point mutations lead to
polymerization of neuroserpin, and that this in turn slows
the trafﬁcking of the mutant protein from the ER, thereby
causing polymer accumulation in the ER lumen. The parallel
analysis of different mutations has allowed us to establish
that the severity of the trafﬁcking defect correlates directly
with the severity of the disease phenotype. Finally, we show
that the long-term accumulation of neuroserpin polymers
within neurons causes a locomotor deﬁcit in ﬂies, supporting
the hypothesis that serpin polymers are the toxic species in
FENIB.
Our previous work has characterized the trafﬁcking of S49P
and S52R mutants of neuroserpin that underlie mild/moderate
forms of FENIB (27). We now demonstrate that H338R and
G392E neuroserpin also form polymers that are retained as
intracellular inclusions when transiently expressed in COS-7
cells (Fig. 1). When all four mutants were analysed in parallel,
the degree of retention was directly proportional to the length
of the polymers and the severity of the clinical phenotype
caused by each mutation. Thus, the mutant of neuroserpin
that causes the most severe clinical phenotype, G392E neuro-
serpin, formed the longest chain polymers and showed the
greatest degree of intracellular retention followed by H338R,
S52R and S49P neuroserpin (Figs 1C and 3). No polymers
were detected following the expression of wild-type neuroser-
pin (Figs 1C and 2C). These data provide strong experimental
support for molecular models predicting the propensity of neu-
roserpin mutants to form polymers in vivo. We conﬁrmed the
presence of polymers using a novel conformer speciﬁc anti-
neuroserpin polymer monoclonal antibody. This antibody
and digestion with endoglycosidase H, localized the polymer-
ized neuroserpin to the ER, in keeping with previous obser-
vations from patients with FENIB (12) and mice
overexpressing mutant neuroserpin (28), and with ﬁndings
from COS-7 cells transiently transfected with S49P and
S52R neuroserpin (27).
Transient transfection experiments in COS-7 cells do not
provide information on the effects of long-term expression
1534 Human Molecular Genetics, 2008, Vol. 17, No. 11of neuroserpin or how the mutants are handled by the
regulated secretory pathway (22–24). We addressed these
questions by generating stable transfected PC12 lines that con-
ditionally express wild-type, S52R and G392E neuroserpin.
These mutants were selected as they cause moderate and
severe forms of FENIB, respectively. The induction of S52R
and G392E neuroserpin resulted in the formation of polymers
that accumulated within undifferentiated PC12 cells (Fig. 4A).
Figure 5. Polymers of mutant neuroserpin accumulate in the brain of transgenic ﬂies and cause a locomotor phenotype. (A) Levels of total neuroserpin were
determined in transgenic ﬂy homogenates (see Materials and Methods) by sandwich ELISA. (B) Immunohistochemical detection of neuroserpin with the 1A10
monoclonal antibody in the brains of ﬂies expressing the elav promotor (elav), wild-type (Wt), S49P (S49P), S52R (S52R), H338R (H338R) or G392E (G392E)
neuroserpin at day 25 after eclosion. Intracellular accumulation of mutant neuroserpin (brown staining) was located within cortical neuronal cell bodies, adjacent
to the mushroom bodies and lobula. Left and middle panels were taken with a 20  objective, enlarged details in right panels were obtained with a 100  oil
immersion objective. (C) Levels of polymerized neuroserpin were determined in transgenic ﬂy homogenates (see Materials and Methods) by sandwich ELISA
with the 7C6 monoclonal antibody. (D) Cumulative survival plots for a hundred ﬂies of each representative line chosen for each neuroserpin genotype. (E) Trans-
genic ﬂies expressing all ﬁve variants of neuroserpin were subjected to climbing assays (see Materials and Methods) to assess their locomotor performance and
the results were plotted against the levels of neuroserpin polymers detected by ELISA in (C). A negative correlation was found with an R
2 ¼ 0.84 that was
statistically signiﬁcant at P , 0.05.
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protein when the PC12 cells were differentiated into neurons
by treatment with NGF. Wild-type neuroserpin co-localized
with chromogranin A at the tips of neurites, most likely in
the dense-core secretory vesicles (Fig. 4C). It was present as
a mature protein (insensitive to digestion with endoglycosi-
dase H) that was released upon stimulation with high concen-
trations of extracellular potassium (Fig. 4B and D). Thus,
wild-type neuroserpin showed the normal behaviour of a
protein processed through the regulated secretory pathway.
In contrast, G392E neuroserpin was retained within the ER
as an endoglycosidase H sensitive protein that formed poly-
mers when assessed by non-denaturing PAGE and by
immunocytochemistry with our anti-neuroserpin polymer
monoclonal antibody. This would explain the lack of regulated
secretion of this mutant protein after membrane depolarization
with potassium. It is striking that the S52R mutant, which
causes moderately severe FENIB, showed characteristics that
are intermediate between wild-type and G392E neuroserpin.
A proportion of S52R neuroserpin reached the dense-core
secretory vesicles for secretion, whereas a proportion formed
polymers that accumulated within the ER. These ﬁndings
underscore the correlation between the polymerization and
trafﬁcking defects of the different mutations of neuroserpin
and the severity of the clinical phenotype of FENIB.
A similar correlation between polymer formation and intra-
cellular retention has been described for point mutations in
the serpin a1-antitrypsin. The Z mutation (Glu342Lys)
causes a1-antitrypsin to form polymers within hepatocytes
more rapidly than the milder S (Glu264Val) or I (Arg39Cys)
variants (30). This is associated with a greater retention of
intracellular Z a1-antitrypsin, which in turn is associated
with more inclusions, a greater risk of liver disease and
more severe plasma deﬁciency. This genotype–phenotype
correlation was established by correlating the rate of a1-
-antitrypsin polymerization in vitro with the clinical manifes-
tations caused by each mutant of a1-antitrypsin (8). Our
current study is the ﬁrst to provide a direct correlation
between the intracellular formation of serpin polymers and
the severity of a clinical phenotype of a serpinopathy.
Our ﬁndings raise the important and unresolved question of
whether the retention of intracellular polymers is intrinsically
toxic. This was assessed in a whole organism by expressing
wild-type neuroserpin and the mutants that cause FENIB in
the neurones of ﬂies. In all cases, the protease inhibitory
activity of neuroserpin was removed by expressing the
protein with Pro–Pro residues in the P1–P10 positions of the
reactive site loop. P1–P10 Pro–Pro wild-type neuroserpin
was not retained within neurones and had no effect on the
longevity of the ﬂies or their locomotor performance
(Fig. 5). In contrast, the mutant forms of neuroserpin formed
polymers that accumulated heterogeneously within the cell
bodies of cortical neurones (Fig. 5). This was despite the ubi-
quitous expression of neuroserpin in all neurones of the brain.
The distribution of neuroserpin inclusions in ﬂies resembles
the distribution in the brains of patients (12,13) and in
mouse models (28) of FENIB. The degree of protein accumu-
lation was directly proportional to the severity of the disease
phenotype caused by each mutation and mirrored the ﬁndings
from both transiently transfected COS-7 cells and the
conditional expression of neuroserpin in PC12 cells. The
expression of the different forms of neuroserpin had no
effect on the longevity of the ﬂies, but there was a progressive
reduction in ﬂy locomotor function that correlated with the
quantity of neuroserpin polymers in the brain (Fig. 5). These
data provide strong evidence that the accumulation of poly-
mers within neurones is neurotoxic in vivo. Moreover, the
level of toxicity is directly proportional to the quantity of
intracellular polymers. An alternative explanation of our
results is that folding intermediates of mutant neuroserpin
cause toxicity prior to polymerization. However, the
expression of the Z mutant of a1-antitrypsin does not activate
the unfolded protein response (31–33), which indicates that
polymerogenic serpins do not cause ER stress through the
accumulation of mis-folded intermediates. It has recently
been proposed that Z a1-antitrypsin polymers are sequestered
within ER derived inclusion bodies, protecting the cells from
toxicity and allowing normal ER function (34). Although
this seems probable in the short term and agrees with the
lack of a strong toxicity phenotype in our cell and ﬂy
models of disease, the locomotor phenotype that we observe
in ﬂies that express mutant neuroserpin supports the toxicity
of long-term accumulation of polymers within cells. Previous
work has shown that the accumulation of the polymerogenic Z
mutant of a1-antitrypsin in cell models and in the livers of
transgenic mice causes the activation of NF-kappa
B (nuclear factor kappa B) (31,32), a hallmark of the ER over-
load response (35,36). The toxicity of neuroserpin polymers
may also be mediated through this pathway.
In summary, mutants of neuroserpin form polymers within
the ER at a level that is directly proportional to the severity
of the clinical phenotype caused by these mutations. The
degree of intracellular accumulation of polymers correlates
with the severity of the progressive decline in locomotor func-
tion in Drosophila models of FENIB. Taken together these
data allow us to conclude that neuroserpin polymers have an
intrinsic toxicity that directly contributes to the clinical pheno-
type of FENIB.
MATERIALS AND METHODS
Reagents and antibodies
Unless stated otherwise, reagents, buffers, culture media and
serum for cell cultures were from Sigma-Aldrich Co.
(Dorset, UK). Custom made rabbit polyclonal anti-neuroserpin
antibody (18), rabbit polyclonal anti-GAPDH, donkey poly-
clonal anti-rabbit IgG (Texas Red), anti-goat IgG (FITC)
and anti-mouse IgG (FITC) antibodies were from Abcam
(Cambridge, UK). Goat polyclonal anti-rabbit IgG (HRP),
rabbit polyclonal anti-mouse IgG (HRP), goat polyclonal anti-
mouse IgG, mouse peroxidase anti-peroxidase complex
(mouse PAP) and rabbit polyclonal anti-ERGIC-53/p58 anti-
bodies were from Sigma-Aldrich Co. Goat polyclonal
anti-calreticulin and anti-chromogranin A antibodies were
from Santa Cruz Biotechnology (through Autogen Bioclear,
Mile Elm Calne, UK). Mouse monoclonal anti-GM130 anti-
body was from BD Biosciences Pharmigen (Oxford, UK).
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The plasmids expressing human wild-type, S49P and S52R
neuroserpin are described in (27). H338R and G392E neuro-
serpin were generated from wild-type neuroserpin by site-
directed mutagenesis with the QuikChange Site-Directed
Mutagenesis kit (Stratagen, La Jolla, CA, USA). Wild-type,
S52R and G392E neuroserpin were subcloned into the pTRE-
Tight vector (BD Biosciences, Oxford, UK) for the generation
of the stable PC12 Tet-On neuroserpin cell lines.
Cos-7 cell cultures, DNA transfections and analysis
COS-7 cells were maintained and transfected with DNA as
described previously (27). SDS and non-denaturing PAGE fol-
lowed by western-blot analysis, metabolic labelling and
immunoprecipitation and immunocytochemistry for confocal
microscopy were performed as described previously (27).
Generation and characterization of stable Tet-On PC12
cells lines expressing neuroserpin
The PC12 Tet-On cell line was purchased from BD Bio-
sciences. Stable PC12-neuroserpin cell lines were generated
following the instructions from BD Biosciences and screened
for neuroserpin expression by ELISA (see below). The cells
were cultured in DMEM supplemented with 10% v/v heat
inactivated horse serum, 5% v/v Tet Approved FBS (BD Bio-
sciences), 1% v/v HEPES buffer, 0.2 U/ml bovine insulin,
200 mg/ml Geneticin and 100 mg/ml Hygromycin B (both
selective antibiotics from Invitrogen, Paisley, UK), at 378C
and 5% v/v CO2 in a humidiﬁed incubator. Neuroserpin
expression was typically induced for 4 days with 10 mg/ml
doxycycline. SDS and non-denaturing PAGE followed by
western-blot analysis and immunocytochemistry for confocal
microscopy were performed as described previously (27).
Rabbit anti-neuroserpin polyclonal antibody was diluted at
1:750, anti-neuroserpin monoclonal antibodies were used
at 1 mg/ml, anti-calreticulin and anti-GM130 were used at
1 mg/ml, anti-chromogranin A was used at 4 mg/ml,
anti-ERGIC-53/p58 was used at 5 mg/ml and donkey second-
ary anti-rabbit IgG (Texas Red), anti-goat IgG (FITC) and
anti-mouse IgG (FITC) antibodies were used at 1.3 ng/ml.
To assess the regulated secretion, cells were treated with
1 ml/well of control or release buffer (control: 5 mM KCl,
125 mM NaCl, 1.2 mM MgCl2,1 mM ZnCl2, 4.5 g/l w/v
D-glucose, 25 mM hepes, 5.2 mM CaCl2; release: same as
control except 55 mM KCl and 70 mM NaCl) for 15 min at
378C. The supernatants were cleared by spinning at 500 g
for 10 min and the cell lysates were prepared as described pre-
viously (27).
PC12 cells were differentiated into neurones by plating onto
glass coverslips pre-treated with 0.1 mg/ml poly-L-lysine and
0.1 mg/ml rat tail collagen I and culturing in DMEM sup-
plemented with 1% v/v heat inactivated horse serum, non-
essential amino acids, HEPES buffer, 0.2 U/ml bovine
insulin, 200 mg/ml Geneticin100 mg/ml Hygromycin B and
150 ng/ml nerve growth factor for 7 days.
Production of the anti-neuroserpin monoclonal
antibodies
Mice immunizations and spleen isolation were carried out by
Harlan Sera-Lab (Belton, Leicestershire, UK). Three mice
were immunized with recombinant S49P neuroserpin poly-
mers (ﬁve doses of 10, 20 and 40 mg, respectively) and one
was immunized with S49P neuroserpin polymers extracted
from neuroserpin inclusions isolated from patients with
FENIB (26) (ﬁve doses of 8 mg). The production of hybridoma
cell lines was carried out as described previously (37,38). The
hybridoma clones were screened by antigen-mediated ELISA
using puriﬁed recombinant wild-type neuroserpin or S49P
neuroserpin polymers as the antigen. Selected clones were
sub-cloned by limited dilution and expanded as cell lines.
Sandwich ELISA
Unless stated otherwise, all steps were carried out at room
temperature and using 50 ml/well. Plates (Corning Inc.,
Costar 3590) were coated overnight at 48C with antigen-
puriﬁed rabbit polyclonal anti-neuroserpin antibody at 2 mg/
ml in 0.2 M Na2CO3/NaHCO3 pH 9.4. Next, wells were
washed with 0.9% w/v NaCl, 0.05% v/v Tween20 and
blocked for 2 h with 300 ml/well of blocking buffer (PBS,
0.25% w/v BSA, 0.05% v/v Tween20, 0.025% w/v Na
azide). Standards (recombinant puriﬁed wild-type or polymer-
ized mutant neuroserpin) and unknown samples (cell lysates
prepared as for western-blot, culture medium supernatants or
ﬂy extracts, see below) were diluted in blocking buffer and
incubated for 2 h. After washing, the wells were incubated
with either a pool of monoclonal antibodies (1A10, 10B8
and 10G12, each 333 ng/ml) or with an individual monoclonal
antibody (1 mg/ml) diluted in blocking buffer for 2 h. Bound
monoclonal antibodies were detected with rabbit anti-mouse
HRP antibody (1:20000 in blocking buffer without Na azide)
for 1 h. After developing for 10 min with TMB substrate sol-
ution (Sigma-Aldrich Co, Dorset, UK) and stopping the reac-
tion with 1 M H2SO4, HRP activity was measured in a plate
reader (Molecular Devices, Thermo-max microplate reader)
at 450 nm.
Fly culture and generation of transgenic ﬂies
All stocks were in a w
1118 background, cultured on standard
ﬂy food with dried yeast and maintained at 298C. Transgene
expression was driven with the elav-Gal4 pan-neuronal
driver or the GMR-Gal4 retinal driver, as indicated. Trans-
genic ﬂy lines containing wild-type, S49P, S52R, H338R
and G392E neuroserpin transgenes were generated with the
human secretion signal peptide in the Gal4-responsive
pUAST expression vector. Relative expression levels were
determined with reverse-transcriptase quantitative PCR
(RT–qPCR) and transgene expression was found to vary by
less than 8-fold between lines. Representative lines, chosen
according to their level of neuroserpin accumulation, were
used in all experiments.
Human Molecular Genetics, 2008, Vol. 17, No. 11 1537Preparation of ﬂy samples for ELISA
Female ﬂies were collected 35 days after eclosion. Three ali-
quots of ﬁve whole ﬂies were homogenized in 100 mlo f
150 mM NaCl, 50 mM Tris pH 7.5, 5 mM EDTA and protease
inhibitor cocktail tablets (Roche) using mortar and pestle
(Fisher Scientiﬁc, Loughborough, UK). After clearing by cen-
trifugation (16000 g for 15 min), the supernatant was retrieved
avoiding any lipid droplets.
Immunohistochemistry in ﬂy sections
Heads were dissected from female ﬂies 25 days after eclosion.
Parafﬁn sections were deparafﬁnated, rehydrated and treated
for 10 min in the dark with 10% v/v methanol, 3% v/v H2O2
in PBS to inactivate endogenous peroxidase activity. Sections
were then incubated with 1A10 monoclonal antibody at 25 mg/
ml in blocking reagent (PBS, 10% w/v BSA, 0.1% v/v Triton
X-100, 0.1% w/v Na azide) overnight at room temperature.
After three washes in PBS, sections were incubated with anti-
mouse IgG at 80 mg/ml for 45 min and mouse PAP complex at
1:200 for 30 min (in Na azide free-blocking reagent), with
three washes in PBS after each incubation step. HRP activity
was developed with SIGMAFAST-DAB tablets (Sigma-
Aldrich Co., Dorset, UK) and sections were subsequently
dehydrated and mounted with DePex (VWR International,
Lutterworth, UK). Pictures were obtained in a Zeiss AxioS-
kope2 microscope using AxioVision software.
Climbing assays
Climbing assays were performed as previously described (39).
Brieﬂy, female ﬂies were transferred to 25 ml pipettes in
groups of 15. Flies were tapped down to the bottom of the
tube and 30 s later the number of ﬂies at the top and at the
bottom were counted. Each tube was tested three times. Two
or three cohorts of 15 ﬂies were tested for each genotype.
The performance index (PI) for each tube of ﬂies was calcu-
lated as PI ¼ 0.5 ((Total ﬂiesþﬂies at top2ﬂies at
bottom)/total ﬂies) to give a score between 0 and 1.
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